专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US5091390A Treatment of CNS disorders with 4,5,6,7-tetrahydro-1H-imidazo (4,5-)-pyridines and analogs 失效
标题翻译：用4,5,6,7-四氢-1H-咪唑并（4,5 - ） - 吡啶和类似物治疗CNS障碍
公开(公告)号：US5091390A
公开(公告)日：1992-02-25
申请号：US585422
申请日：1990-09-20
申请人： Robert J. Ardecky , Andrew T. Chiu , John J. V. Duncia , Petrus B. M. W. M. Timmermans , Ruth R. Wexler
发明人： Robert J. Ardecky , Andrew T. Chiu , John J. V. Duncia , Petrus B. M. W. M. Timmermans , Ruth R. Wexler
IPC分类号： C07D471/04
CPC分类号： C07D471/04
摘要： Provided are 4,5,6,7-tetrahydro-1H-imidazo(4,5-c)-pyridine derivatives, methods for preparing them, pharmaceutical compositions containing them, and methods of using them to treat disorders of mammals mediated by AII type-2 receptors in the central nervous system.
摘要翻译：提供了4,5,6,7-四氢-1H-咪唑并（4,5-c） - 吡啶衍生物，其制备方法，含有它们的药物组合物及其用于治疗由AII型介导的哺乳动物疾病的方法 -2受体在中枢神经系统。

12. 发明授权

US06365587B1 Substituted aryl hydroxamic acids as metalloproteinase inhibitors 有权
标题翻译：取代的芳基异羟肟酸作为金属蛋白酶抑制剂
公开(公告)号：US06365587B1
公开(公告)日：2002-04-02
申请号：US09312066
申请日：1999-05-13
申请人： Matthew E. Voss , Carl P. Decicco , Ruth R. Wexler
发明人： Matthew E. Voss , Carl P. Decicco , Ruth R. Wexler
IPC分类号： A61K31541
CPC分类号： C07D401/12 , C07D207/16 , C07D279/12 , C07D417/12
摘要： The present application describes novel substituted aryl hydroxamic acids of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring A is a 5-8 membered ring containing from 0-1 additional heteroatoms selected from N, O, and S, which are useful as metalloprotease inhibitors.
摘要翻译：本申请描述了式I的新型取代的芳基异羟肟酸或其药学上可接受的盐形式，其中环A是含有0-1个另外选自N，O和S的杂原子的5-8元环，其可用作金属蛋白酶抑制剂。

13. 发明授权

US4576958A Antihypertensive 4,5-diaryl-1H-imidazole-2-methanol derivatives 失效
标题翻译：抗高血压4,5-二芳基-1H-咪唑-2-甲醇衍生物
公开(公告)号：US4576958A
公开(公告)日：1986-03-18
申请号：US573214
申请日：1984-01-23
申请人： Ruth R. Wexler
发明人： Ruth R. Wexler
IPC分类号： C07D233/54 , C07D233/64 , A61K31/415
CPC分类号： C07D233/64
摘要： Antihypertensive 4-phenyl-5-(4-methylsulfonylphenyl)-.alpha.,.alpha.-bis(trifluoromethyl)-1H-imidazole-2-methanol derivatives are useful in the treatment of hypertension.
摘要翻译：抗高血压4-苯基-5-（4-甲基磺酰基苯基）-α，α-双（三氟甲基）-1H-咪唑-2-甲醇衍生物可用于治疗高血压。

14. 发明授权

US07109339B2 Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists 有权
标题翻译：取代三环γ-咔啉作为血清素受体激动剂和拮抗剂
公开(公告)号：US07109339B2
公开(公告)日：2006-09-19
申请号：US10743449
申请日：2003-12-19
申请人： Taekyu Lee , Wenting Chen , Wei Deng , Albert J. Robichaud , Ruth R. Wexler
发明人： Taekyu Lee , Wenting Chen , Wei Deng , Albert J. Robichaud , Ruth R. Wexler
IPC分类号： C07D417/00 , C07D471/04
CPC分类号： C07D471/04
摘要： The present invention is directed to novel compounds represented by structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R4a, R5, R6, R7, R8, R9,and m, are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain central nervous system disorders. The compounds of this invention are serotonin receptor modulators, in particular 5HT2C receptor agonists and antagonists, and are useful in the control or prevention of central nervous system disorders including obesity, anorexia, bulemia, depression, anxiety, psychosis, schizophrenia, migraine, addictive behavior, obsessive-compulsive disorder, and sexual disorders.
摘要翻译：本发明涉及由结构式（I）表示的新化合物或其药学上可接受的盐，其中R 1，R 4a，R 5， R 6，R 6，R 7，R 8，R 9和M如本文所定义。本发明还涉及包含这些新化合物作为活性成分的药物制剂以及新型化合物及其制剂在治疗某些中枢神经系统疾病中的用途。本发明的化合物是5-羟色胺受体调节剂，特别是5HT 2C受体激动剂和拮抗剂，并且可用于控制或预防中枢神经系统疾病，包括肥胖症，厌食症，血症，抑郁症，焦虑症，精神病，精神分裂症，偏头痛，成瘾行为，强迫症和性功能障碍。

15. 发明授权

US5478830A Fused-ring heterocycles for the treatment of atherosclerosis 失效
标题翻译：用于治疗动脉粥样硬化的融合环杂环
公开(公告)号：US5478830A
公开(公告)日：1995-12-26
申请号：US889892
申请日：1992-05-29
申请人： C. Anne Higley , Ruth R. Wexler , Richard G. Wilde
发明人： C. Anne Higley , Ruth R. Wexler , Richard G. Wilde
IPC分类号： C07D487/04 , A61K31/44 , A61K31/505 , A61K31/52
CPC分类号： C07D487/04
摘要： This invention relates to pyrazolo pyrimidines for the treatment of atherosclerosis as inhibitors of acyl--CoA, cholesterol acyetransferase (ACAT), and their use as antihypercholesterolemic agents, pharmaceutical compositions and preparation, and having the formula (I): ##STR1## wherein: A and Q are selected independently from CH or N with no more than two nitrogens per ring:D, E, and G are selected independently from CR.sup.1 or N with no more than two nitrogens per ring;X is S(O).sub.r, O, NR.sup.4 or CH.sup.2 ;J is C.sub.2 -C.sub.10 alkyl, C.sub.3 -C.sub.10 branched alkyl, C.sub.3 -C.sub.10 alkenyl or C.sub.3 -C.sub.10 alkynyl;Y is O, S, H.sub.2 or NH:Z is NHR.sup.3, OR.sup.3 or R.sup.3 :R.sup.1 is selected independently from H, NO.sub.2, Br, Cl, F, CF.sub.3, CN, CH.sub.3 S(O).sub.r, C.sub.1 -C.sub.8 alkyl or alloxy, C.sub.3 -C.sub.8, branched alkyl, C.sub.1 -C.sub.4 carboalkoxy, NR.sup.5 R.sup.6 or NR.sup.5 COR.sup.6 ;R.sup.2 is C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.8 branched alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.3 -C.sub.8 alkenyl or alkynyl, C.sub.7 -C.sub.14 araalkyl where the aryl group is optionally substituted; phenyl optionally substituted benzyl optionally substituted 2-, 3-, or 4- pyridinyl, pyrimidinyl: or biphenyl:R.sup.3 is C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.8 branched alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.4 -C.sub.10 cycloallylalkyl, C.sub.3 -C.sub.6 alkenyl or alkynyl, C.sub.1 -C.sub.3 perfluoroalkyl, C.sub.7 -C.sub.14 araalkyl where the aryl group is optionally substituted phenyl optionally substituted benzyl optionally substituted 2-, 3-, or 4- pyridinyl, pyrimidinyl; or biphenyl:R.sup.4 is H, C.sub.1 -C.sub.6 alkyl or benzyl;R.sup.5 and R.sup.6 are selected independently from H or C.sub.1 -C.sub.4 alkyl;r is 0 to 2:or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明涉及用于治疗动脉粥样硬化的吡唑并嘧啶作为酰基辅酶A，胆固醇转氨酶（ACAT）的抑制剂及其作为抗高胆固醇血症药物，药物组合物和制剂的用途，并具有式（I）：其中： A和Q独立地选自CH或N，每个环不多于两个氮：D，E和G独立地选自CR1或N，每个环不多于两个氮; X是S（O）r，O，NR 4或CH 2; J是C 2 -C 10烷基，C 3 -C 10支链烷基，C 3 -C 10链烯基或C 3 -C 10炔基; Y是O，S，H2或NH：Z是NHR3，OR3或R3：R1独立地选自H，NO2，Br，Cl，F，CF3，CN，CH3S（O）r，C1-C8烷基或烯氧基， C3-C8，支链烷基，C1-C4烷氧羰基，NR5R6或NR5COR6; R2是C1-C8烷基，C3-C8支链烷基，C3-C7环烷基，C3-C8链烯基或炔基，其中芳基任选被取代的C7-C14芳烷基; 苯基任选取代的苄基任选取代的2-，3-或4-吡啶基，嘧啶基或联苯基：R3是C1-C8烷基，C3-C8支链烷基，C3-C7环烷基，C4-C10环烯基烷基，C3-C6烯基或炔基，C1-C3全氟烷基，C7-C14芳烷基，其中芳基是任选取代的苯基任选取代的苄基任选取代的2-，3-或4-吡啶基，嘧啶基; 或联苯基：R 4是H，C 1 -C 6烷基或苄基; R 5和R 6独立地选自H或C 1 -C 4烷基; r为0〜2：或其药学上可接受的盐。

16. 发明授权

US5310748A Imidazoles for the treatment of atherosclerosis 失效
标题翻译：咪唑用于治疗动脉粥样硬化
公开(公告)号：US5310748A
公开(公告)日：1994-05-10
申请号：US881034
申请日：1992-05-11
申请人： Richard G. Wilde , C. Anne Higley , Jeffrey T. Billheimer , Ruth R. Wexler
发明人： Richard G. Wilde , C. Anne Higley , Jeffrey T. Billheimer , Ruth R. Wexler
IPC分类号： C07D233/84 , C07D401/12 , C07D403/12 , A61K31/415
CPC分类号： C07D401/12 , C07D233/84
摘要： Disclosed are imidazoles as inhibitors of acylCoA:cholesterol acyltransferase (ACAT), processes for their preparation, pharmaceutical compositions, and their use as antihypercholesterolemics and/or antiatherosclerotics.
摘要翻译：公开了作为酰基CoA的抑制剂的咪唑：胆固醇酰基转移酶（ACAT），其制备方法，药物组合物及其作为抗高胆固醇血症和/或抗动脉粥样硬化的用途。

17. 发明授权

US5290801A Benzimidazoles for the treatment of atherosclerosis 失效
标题翻译：苯并咪唑用于治疗动脉粥样硬化
公开(公告)号：US5290801A
公开(公告)日：1994-03-01
申请号：US889909
申请日：1992-05-29
申请人： C. Anne Higley , Thomas P. Muduskuie, Jr. , Ruth R. Wexler , Richard G. Wilde
发明人： C. Anne Higley , Thomas P. Muduskuie, Jr. , Ruth R. Wexler , Richard G. Wilde
IPC分类号： A61K31/415 , A61K31/42 , A61K31/425 , A61K31/44 , A61K31/495 , A61K31/50 , A61K31/505 , A61K31/52 , C07D235/28 , C07D263/58 , C07D277/74 , C07D471/04 , C07D473/04
CPC分类号： C07D263/58 , A61K31/415 , A61K31/42 , A61K31/425 , A61K31/44 , A61K31/495 , A61K31/50 , A61K31/505 , A61K31/52 , C07D235/28 , C07D277/74 , C07D471/04 , C07D473/04
摘要： This invention relates to imidazoles, namely, fused-ring heterocycles as inhibitors of acyl-CoA: cholesterol acyltransferase (ACAT), pharmaceutical compositions containing them, processes for their preparation, and their use as antihypercholesterolemic and/or antiatherosclerotic agents for the treatment of atherosclerosis.
摘要翻译：本发明涉及咪唑，即作为酰基辅酶A的抑制剂的稠环杂环：胆固醇酰基转移酶（ACAT），含有它们的药物组合物，其制备方法及其作为抗高胆固醇血和/或抗动脉粥样硬化剂用于治疗动脉粥样硬化的用途。

18. 发明授权

US5166214A Use of imidazoles for the treatment of atherosclerosis 失效
公开(公告)号：US5166214A
公开(公告)日：1992-11-24
申请号：US533241
申请日：1990-06-04
申请人： Jeffrey T. Billheimer , Peter J. Gillies , C. Anne Higley , Thomas P. Maduskuie, Jr. , Ruth R. Wexler
发明人： Jeffrey T. Billheimer , Peter J. Gillies , C. Anne Higley , Thomas P. Maduskuie, Jr. , Ruth R. Wexler
IPC分类号： C07D233/54 , C07D233/70 , C07D233/84 , C07D233/88 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D409/04 , C07D409/14 , C07D491/04
CPC分类号： C07D233/64 , C07D233/70 , C07D233/84 , C07D233/88 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D409/04 , C07D409/14 , C07D491/04
摘要： This invention relates to imidazoles as inhibitors of acyl-CoA: cholesterol acyltransferase (ACAT), processes for their preparation, and their use as antihypercholesterolemic agents or antiatherosclerotic.The compounds for use in the described method are compounds of Formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are selected independently from H, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.8 branched alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, C.sub.7 -C.sub.14 araalkyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.8 branched alkyl, CH.sub.3 S(O).sub.r, NO.sub.2, CF.sub.3, or NR.sup.7 R.sup.8 ; R.sup.3 is H, C.sub.1 -C.sub.6 alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl, CH.sub.3, CH.sub.3 O, or CF.sub.3 ; R.sup.4 is straight chain C.sub.1 -C.sub.8 alkyl optionally substituted with F; C.sub.3 -C.sub.8 branched alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, C.sub.7 -C.sub.14 aralkyl where the aryl group is optionally substituted with 1 to 3 groups selected from C.sub.1 -C.sub.4 alkyl or alkoxy, F, Br, Cl, NH.sub.2, OH, CN, CO.sub.2 H, CF.sub.3, NO.sub.2, C.sub.1 -C.sub.4 carboalkoxy, NR.sup.7 R.sup.8, or NCOR.sup.7 ; C.sub.3 -C.sub.6 alkenyl or alkynyl, C.sub.1 -C.sub.3 perfluoroalkyl, phenyl optionally substituted with 1 to 3 groups selected from C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.8 branched alkyl, C.sub.1 -C.sub.4, alkoxy, F, Br, Cl, NH.sub.2, OH, CN, CO.sub.2 H, CF.sub.3, NO.sub.2, C.sub.1 -C.sub.4 carboalkoxy, NR.sup.7 R.sup.8 or NCOR.sup.7 ; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C.sub.1 -C.sub.4 alkyl or alkoxy, F, Br, Cl, NH.sub.2, OH, CN, CO.sub.2 H, CF.sub.3, NO.sub.2, C.sub.1 -C.sub.4 carboalkoxy, NR.sup.7 R.sup.8, or NCOR.sup.7 ; 2-, 3-, or 4- or pyrindinyl, pyrimidinyl, or biphenyl; R.sup.5 is H, C.sub.1 -C.sub.6 alkyl, or benzyl; R.sup.6 is C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.8 branched alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.3 -C.sub.8 alkenyl of alkynyl, phenyl optionally substituted with 1 to 3 groups selected from C.sub.1 -C.sub.4 alkyl or alkoxy, F, Br, Cl, NH.sub.2, OH, CN, CO.sub.2 H, CF.sub.3, NO.sub.2, C.sub.1 -C.sub.4 carboalkoxy, NR.sup.7 R.sup.8, or NCOR.sup.7 ; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C.sub.1 -C.sub.4 alkyl or alkoxy, F, Br, Cl, NH.sub.2, OH, CN, CO.sub.2 H, CF.sub.3, NO.sub.2, C.sub.1 -C.sub.4 carboalkoxy, NR.sup.7 R.sup.8, or NCOR.sup.7 ; R.sup.7 and R.sup.8 are selected independently from H or C.sub.1 -C.sub.4 alkyl; A is C.sub.2 -C.sub.10 alkyl, C.sub.3 -C.sub.10 branched alkyl, C.sub.3 -C.sub.10 alkenyl, or C.sub.3 -C.sub.10 alkynyl; Y is O; Z is NHR.sup.4, OR.sup.4, or R.sup.4 ; r is 0-2, or a pharmaceutically acceptable salt thereof.

19. 发明授权

US06268379B1 Substituted aryl hydroxamic acids as metalloproteinase inhibitors 有权
标题翻译：取代的芳基异羟肟酸作为金属蛋白酶抑制剂
公开(公告)号：US06268379B1
公开(公告)日：2001-07-31
申请号：US09311168
申请日：1999-05-13
申请人： Chu-Biao Xue , Carl P. Decicco , Ruth R. Wexler
发明人： Chu-Biao Xue , Carl P. Decicco , Ruth R. Wexler
IPC分类号： C07D21700
CPC分类号： C07D401/12 , C07D405/12
摘要： The present application describes novel substituted aryl hydroxamic acids of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring A is a 5-8 membered ring containing from 0-2 heteroatoms selected from N, 0, and S, which are useful as metalloprotease inhibitors.
摘要翻译：本申请描述了式I的新型取代的芳基异羟肟酸：或其药学上可接受的盐形式，其中环A是含有0-2个选自N，O和S的杂原子的5-8元环，其可用作金属蛋白酶抑制剂。

20. 发明授权

US5318984A Imidazoles for the treatment of atherosclerosis 失效
公开(公告)号：US5318984A
公开(公告)日：1994-06-07
申请号：US940372
申请日：1992-09-03
申请人： Jeffrey T. Billheimer , Peter J. Gillies , C. Anne Higley , Thomas P. Maduskuie, Jr. , Ruth R. Wexler
发明人： Jeffrey T. Billheimer , Peter J. Gillies , C. Anne Higley , Thomas P. Maduskuie, Jr. , Ruth R. Wexler
IPC分类号： C07D233/54 , C07D233/70 , C07D233/84 , C07D233/88 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D409/04 , C07D409/14 , C07D491/04 , A61K31/415 , C07D233/66
CPC分类号： C07D233/64 , C07D233/70 , C07D233/84 , C07D233/88 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D409/04 , C07D409/14 , C07D491/04
摘要： Disclosed are compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 are selected independently from H, C.sub.1 -C.sub.8 unbranched alkyl, C.sub.3 -C.sub.8 branched alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, C.sub.7 -C.sub.14 araalkyl, 2-, 3- or 4-pyridinyl, 2-thienyl, 2-furanyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.8 branched alkyl, CH.sub.3 S(O).sub.r, NO.sub.2, CF.sub.3, or NR.sup.7 R.sup.8 ; or ##STR2## where L is O, O(CH.sub.2).sub.m+1 O, or (CH.sub.2).sub.m where m is 0-4; R.sup.3 is H, C.sub.1 -C.sub.6 alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl, CH.sub.3, CH.sub.3 O, or CF.sub.3 ;R.sup.4 is straight chain C.sub.1 -C.sub.8 alkyl optionally substituted with F; C.sub.3 -C.sub.8 branched alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, C.sub.7 -C.sub.14 araalkyl where the aryl group is optionally substituted with 1 to 3 groups selected from C.sub.1 -C.sub.4 alkyl or alkoxy, F, Br, Cl, NH.sub.2, OH, CN, CO.sub.2 H, CF.sub.3, NO.sub.2, C.sub.1 -C.sub.4 carboalkoxy, NR.sup.7 R.sup.8, or NCOR.sup.7 ; C.sub.3 --C.sub.6 alkenyl or alkynyl, C.sub.1 -C.sub.3 perfluoroalkyl, phenyl optionally substituted with 1 to 3 groups selected from C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.8 branched alkyl, C.sub.1 -C.sub.4 alkoxy, F, Br, Cl, NH.sub.2, OH, CN, CO.sub.2 H, CF.sub.3, NO.sub.2, C.sub.1 -C.sub.4 carboalkoxy, NR.sup.7 R.sup.8 or NCOR.sup.7 ; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C.sub.1 -C.sub.4 alkyl or alkoxy, F, Br, Cl, NH.sub.2, OH, CN, CO.sub.2 H, pyrimidinyl, or biphenyl;R.sup.5 is H, C.sub.1 -C.sub.6 alkyl, or benzyl;R.sup.6 is C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.8 branched alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.3 -C.sub.8 alkenyl or alkynyl, phenyl optionally substituted with 1 to 3 groups selected from C.sub.1 -C.sub.4 alkyl or alkoxy, F, Br, Cl, NH.sub.2, OH, CN, CO.sub.2 H, CF.sub.3, NO.sub.2, C.sub.1 -C.sub.4 carboalkoxy, NR.sup.7 R.sup.8, or NCOR.sup.7 ; pentafluorophenyl, benzyl optionally substituted with 1 to 3 groups selected from C.sub.1 -C.sub.4 alkyl or alkoxy, F, Br, Cl, NH.sub.2, OH, CN, CO.sub.2 H, CF.sub.3, NO.sub.2, C.sub.1 -C.sub.4 carboalkoxy, NR.sup.7 R.sup.8, or NCOR.sup.7 ;R.sup.7 and R.sup.8 are selected independently from H or C.sub.1 -C.sub.4 alkyl;X is S(O).sub.r, O, NR.sup.5, CH.sub.2 ;A is C.sub.2 -C.sub.10 alkyl, C.sub.3 -C.sub.10 branched alkyl, C.sub.3 -C.sub.10 alkenyl, or C.sub.3 -C.sub.10 alkynyl;Y is O, S, H.sub.2, or NH;Z is NHR.sup.4, OR.sup.4, or R.sup.4 ;r is 0-2,or a pharmaceutically acceptable salt thereof and their use as antihypercholesterolemic agents or antiatherosclerotic agents.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式